1. Home
  2. OSRH vs SYBX Comparison

OSRH vs SYBX Comparison

Compare OSRH & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

HOLD

Current Price

$0.60

Market Cap

14.2M

Sector

N/A

ML Signal

HOLD

Logo Synlogic Inc.

SYBX

Synlogic Inc.

HOLD

Current Price

$1.19

Market Cap

15.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSRH
SYBX
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2M
15.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OSRH
SYBX
Price
$0.60
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
524.2K
72.8K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.90
52 Week High
$12.54
$1.96

Technical Indicators

Market Signals
Indicator
OSRH
SYBX
Relative Strength Index (RSI) 47.90 45.07
Support Level $0.55 $1.15
Resistance Level $0.60 $1.22
Average True Range (ATR) 0.06 0.06
MACD -0.00 0.02
Stochastic Oscillator 34.85 60.87

Price Performance

Historical Comparison
OSRH
SYBX

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: